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Abstract Bevacizumab is thought to normalize tumor
vasculature and restore the blood–brain barrier, decreasing
enhancement and peritumoral edema. Conventional meas-
urements of tumor response rely upon dimensions of
enhancing tumor. After bevacizumab treatment, glioblasto-
mas are more prone to progress as nonenhancing tumor.
The RANO (Response Assessment in Neuro-Oncology)
criteria for glioma response use fluid-attenuated inversion
recovery (FLAIR)/T2 hyperintensity as a surrogate for
nonenhancing tumor; however, nonenhancing tumor can be
difficult to differentiate from other causes of FLAIR/T2
hyperintensity (eg, radiation-induced gliosis). Due to these
difficulties, recent efforts have been directed toward
identifying new biomarkers that either predict treatment
response or accurately measure response of both enhancing
and nonenhancing tumor shortly after treatment initiation.
This will allow for earlier treatment decisions, saving
patients from the adverse effects of ineffective therapies
while allowing them to try alternative therapies sooner. An
active area of research is the use of physiologic imaging,
which can potentially detect treatment effects before
changes in tumor size are evident.
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Introduction
Of the different types of glioma, glioblastoma (GBM) is the
most common and aggressive, with a median survival of 12
to 15 months [1]. Multiple antiangiogenic drugs are
currently in use or in clinical trials for the treatment of
GBM. The prototype, bevacizumab, an antibody to vascular
endothelial growth factor (VEGF), is now commonly used
in the setting of recurrent GBM. However, only a fraction
of patients with malignant gliomas respond to antiangio-
genic therapy, and “response” in this setting is not well
defined [1]. Thus, it is critically important to identify
radiologic biomarkers that can either predict treatment
response or accurately measure response after the initiation
of therapy, thereby improving decision making and ultimately
increasesurvival.Thegoalsofthisarticlearetoreviewcurrent
criteria for glioma response and to discuss new MRI
techniquesthatmayprovide potentialbiomarkersoftreatment
effect.
Criteria for Assessing Glioma Response
Intheassessmentoftreatmentresponse,MRIhastraditionally
beenusedtoevaluatetumorsize.Changesinenhancingtumor
size based on bidimensional measurements are the basis for
both the RANO (Response Assessment in Neuro-Oncology)
criteria, the currently accepted standard criteria for assessing
glioma response, and the previously used standard, the
Macdonald criteria [2]. Although relying on conventional
T1-weighted postcontrast scans worked well in the past in
evaluating treatment response, the widespread adoption of
bevacizumab as salvage chemotherapy has highlighted its
limitations. The limitations stem largely from bevacizumab’s
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abnormal vasculature with a blood–brain barrier that is
significantly more permeable than normal brain tissue [3].
Because of the increased permeability, contrast material
more freely leaks out of tumor capillaries, increasing
enhancement on T1-weighted images. By targeting VEGF,
an active permeability agent and promoter of angiogenesis,
bevacizumab decreases the leak of contrast agent into the
interstitium, diminishing contrast enhancement. Because of
the effects of bevacizumab on tumor vasculature, a reduction
in contrast enhancement may not necessarily reflect a
cytotoxic or cytostatic tumor response. Relying on contrast
enhancement can thus lead to an overestimation of treatment
response, a phenomenon known as “pseudoresponse” [4, 5].
The impact of bevacizumab on radiation necrosis is
another important consideration in assessing radiographic
response. Radiation necrosis is typically associated with
avid enhancement, edema, and potentially mass effect,
making it difficult to distinguish from tumor. Because of
the potential similarity with true tumor progression,
radiation changes can lead to “pseudoprogression” [4, 5].
It is estimated that in 20% to 30% of patients with GBM,
the first postradiation MRI shows an increase in contrast
enhancement that subsides with time without any change in
therapy, and may therefore represent radiation change,
rather than true tumor progression [2, 5]. However, no
careful studies have been performed that have determined
whether these sometimes minor enhancements are truly
confused with tumor progression by an experienced
interpreter in a clinical setting. And it also is likely that
ambiguities in interpretation can often be resolved on close
interval follow-up. Thus, the 20% to 30% figure reported
may be a substantial overestimation of clinically relevant
“pseudoprogression.” Regardless, the physiologies under-
lying tumoral necrosis and radiation necrosis are similar, as
they both are associated with leaky vasculature and
increased levels of VEGF [6]. This provides a mechanism
whereby they respond similarly to bevacizumab: in the
same way that bevacizumab can improve the radiographic
appearance of necrotic tumor, it can also substantially
improve the radiographic appearance of radiation necrosis
by decreasing enhancement and edema [7]. It has been
suggested that the responses seen in bevacizumab-treated
patients may be due, at least in part, to palliation of
radiation necrosis rather than true tumor response [7].
To address the limitations in the conventional MRI
assessment of gliomas, the RANO group has developed
new guidelines for treatment response in brain tumors [2].
In contrast to the Macdonald criteria, the RANO criteria
(summarized in Table 1) include fluid-attenuated inversion
recovery (FLAIR) or T2 hyperintensity as a surrogate for
nonenhancing tumor in the determination of progression.
Unfortunately, it does not quantify the amount of FLAIR or
Table 1 Summary of the RANO criteria
Response Criteria
Complete response Disappearance of all enhancing measurable
and nonmeasurable disease sustained for a
minimum of 4 weeks
Stable or improved FLAIR/T2 lesions
No new lesions
Clinical status is stable or improved
Patients cannot be receiving corticosteroids
(physiologic replacement doses are acceptable)
Partial response 50%orgreaterdecrease(comparedwithbaseline)
in the sum of products of perpendicular
diameters of all measurable enhancing lesions
sustained for a minimum
of 4 weeks
No progression of nonmeasurable disease
No new lesions
Stable or improved FLAIR/T2 lesions
Clinical status is stable or improved
The corticosteroid dosage at the time of the
scan should be no greater than the dosage
at the time of the baseline scan
Stable disease Patient does not qualify for complete
response, partial response, or progression
Stable FLAIR/T2 lesions on a corticosteroid
dose no greater than at baseline
Clinical status is stable
Progression Defined by any of the following:
25% or greater increase in sum of the products
of perpendicular diameters of all measurable
enhancing lesions compared with the smallest
tumor measurement obtained either at
baseline or best response following the
initiation of therapy, while on a stable or
increasing dose of corticosteroids.
Significant increase in FLAIR/T2 lesions
compared with baseline or best response
following initiation of therapy, not caused by
comorbid events (eg, radiation therapy,
ischemic injury, seizures, postoperative
changes, or other treatment effects), while on
a stable or increasing dose of corticosteroids
Presence of new lesions
Clinical deterioration not attributable to other
causes apart from the tumor (eg, seizures,
medication side effects, complications of
therapy, cerebrovascular events, infection)
or decreases in corticosteroid dose
Failure to return for evaluation due to death
or deteriorating condition
Clear progression of nonmeasurable disease
FLAIR fluid-attenuatedinversionrecovery,RANO Response Assessment
in Neuro-Oncology. (Adapted from Wen et al. [2])
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differentiating nonenhancing tumor from other causes of
increased FLAIR or T2 signal (eg, radiation effects,
ischemic injury, and infection), the RANO group felt that
an objective criterion for nonenhancing tumor progression
was not currently feasible. Thus, it is clear that methods
separating nonenhancing tumor from gliosis, and true tumor
progression from pseudoprogression, could substantially
improve the accuracy of response measures.
New Imaging Techniques and the Search
for Biomarkers for Glioma Response
Magnetic Resonance Perfusion
The use of perfusion imaging as a biomarker for response
to antiangiogenic drugs has generated significant interest.
There are no validated biomarkers for antiangiogenesis that
are currently available for clinical use.The two mostcommon
methods of perfusion imaging are dynamic susceptibility
contrast (DSC) imaging and dynamic contrast-enhanced
(DCE) imaging. DSC imaging can be used to generate maps
of relative cerebral blood volume (rCBV), relative cerebral
blood flow (rCBF), and mean transit time. Other DSC
parameters include relative peak height, which is correlated
withrCBV,andpercentageofsignalintensityrecovery(PSR),
which is a marker for capillary permeability. DCE imaging is
generally used to measure K-trans, a constant for the rate at
which contrast material moves from the vasculature to the
extracellularspace.K-transisdependentuponthesurfacearea
of capillaries, as well as the leakiness of the capillaries. Thus,
K-transisoftenusedasa markerforthepermeabilityoftumor
vasculature. Using these parameters, many groups have
investigated the role of perfusion imaging in evaluating
gliomas. Table 2 provides a summary of the key findings
from recent magnetic resonance (MR) perfusion studies.
H i r a ie ta l .[ 8] studied 49 patients with high-grade
astrocytomas prior to the initiation of radiation and chemo-
therapy and found that rCBV has prognostic value. Using a
multivariate regression model to control for age and other
clinical features, maximum rCBV was found to be an
independent prognostic factor of survival: the 2-year survival
rate was 67% for patients with a maximum rCBV below 2.3
Study Key finding(s)
DSC perfusion
Prognostic value for standard treatment (chemotherapy and radiation)
Hirai et al. [8] Maximum rCBV was prognostic of 2-year survival in patients with high-grade
astrocytomas
Mangla et al. [14] Change in rCBV was predictive of 1-year survival in patients with glioblastoma
Law et al. [15￿￿] rCBV was predictive of time to progression in both high- and low-grade gliomas
Predictive value for response to antiangiogenic therapy
Sawlani et al. [9] Change in HPV correlated with time to progression in recurrent glioblastoma patients
Akella et al. [13] rCBF was correlated with radiographic and clinical response in patients with malignant
gliomas treated with cilengitide
Differentiating true progression from pseudoprogression
Barajas et al. [18￿￿] DSC parameters (rCBV, rPH, PSR) were significantly different in recurrent
glioblastoma compared with radiation necrosis
Hu et al. [19] An rCBV threshold value of 0.71 differentiated high-grade glioma recurrence from
post-treatment radiation effect with a sensitivity of 91.7% and a specificity of 100%
Sugahara et al. [20] rCBV ratios were>2.6 in cases of recurrent tumor and<0.6 in cases of post-treatment
radiation effect
Gahramanov et al. [23] Ferumoxytol-DSC was more sensitive in detecting true progression than gadoteridol-
DSC
DCE perfusion
Prognostic value for standard treatment (chemotherapy and radiation)
Cao et al. [17] Baseline as well as changes in rCBV were predictive of survival in patients with high-
grade gliomas
Predictive value for response to antiangiogenic therapy
Sorensen et al. [10] Combining K-trans, microvessel volume, and circulating collagen IV was predictive of
overall and progression-free survival in patients with recurrent glioblastoma treated
with cediranib
Cha et al. [12] Changes in rCBV were more strongly correlated with treatment response than
enhancing tumor size in recurrent malignant gliomas treated with thalidomide and
carboplatin
Table 2 Key findings of MR
perfusion studies in the
assessment of gliomas
DCE dynamic contrast
enhanced, DSC dynamic
susceptibility contrast, HPV
hyperperfusion volume, MR
magnetic resonance, PSR
percentage of signal intensity
recovery, rCBV relative cerebral
blood volume, rPH relative peak
height
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when controlling for astrocytoma grade, maximum rCBV
remained prognostic.
Several studies have focused on using perfusion imaging
to assess response to antiangiogenic therapy (ie, as a
predictive rather than prognostic indicator). Sawlani et al.
[9] studied 16 patients with recurrent GBM treated with
bevacizumab and evaluated mean rCBV, mean leakage
coefficient, and hyperperfusion volume (HPV), which is
defined as the fraction of tumor with an rCBV above a
prespecified threshold, as potential biomarkers for treatment
response. They found that the percent change in HPV
(using an rCBV threshold of 1.00) from baseline to first
follow-up had a statistically significant hazard ratio of
1.077 when correlated with time to progression. Although
HPV may have potential as a predictive biomarker, the
hazard ratio was only slightly greater than 1, and the sample
size was small; thus, additional refinements are needed to
improve the clinical utility of this technique.
Sorensen et al. [10] studied 31 patients with recurrent
GBM treated with cediranib, an inhibitor of the VEGF
receptor tyrosine kinases. They calculated a “vascular
normalization index” by combining K-trans, microvessel
volume, and circulating collagen IV. A prior study that used
a mouse model to evaluate the effect of cediranib found that
edema alleviation was associated with a transient increase
in circulating collagen IV, and it was thought that the
increase in circulating collagen IV was reflective of
basement membrane thinning [11]. The authors found that
this new index (measured 1 day after treatment initiation)
was predictive of overall and progression-free survival. The
combination of imaging data with serum assays is a novel
avenue of increasing the sensitivity and specificity of
markers that may prove clinically useful.
Cha et al. [12] studied 18 patients with recurrent
malignant gliomas treated with both thalidomide (an
antiangiogenic agent) and carboplatin and found that
changes in rCBV were more strongly correlated with
treatment response based on clinical status than enhancing
tumor size. In a multicenter trial with 36 patients with
malignant gliomas treated with cilengitide (an angiogenesis
inhibitor), Akella et al. [13] found that rCBF correlated
with radiographic and clinical response. The correlation
between rCBV and radiographic and clinical response
approached significance. Both studies, as well as that from
Sorensen et al. [10] discussed above, suggest that that
perfusion imaging may be useful in the early assessment of
response to angiogenesis inhibitors.
P e r f u s i o ni m a g i n gh a sa l s ob e e ni n v e s t i g a t e da sa
potential biomarker for prognosis following standard
treatment (ie, without antiangiogenic therapy). In a retro-
spective study with 36 GBM patients treated with radiation
and temozolomide, Mangla et al. [14] found that the
percentage change in rCBV from the pre- and post-
treatment measurements (> 5% or≤5%) was predictive of
1-year survival with a sensitivity of 90% and a specificity
of 60%. Patients with increased rCBV had a median
survival of 235 days, whereas those with decreased rCBV
had a median survival of 529 days. In a larger study with
189 patients with low-grade and high-grade gliomas, Law
et al. [15￿￿] found that rCBV could be used to predict time
to progression. Patients with rCBV less than 1.75 had a
median time to progression of 3585 days, whereas patients
with rCBV greater than 1.75 had a median time to
progression of 265 days, indicating that survival in both
high- and low-grade gliomas can be stratified by rCBV. For
low-grade gliomas, increased rCBV may be a marker for
degeneration into high-grade tumors, but Caseiras et al.
[16] demonstrated that tumor growth on T1-weighted
imaging is actually a stronger predictor of malignant
transformation than change in rCBV. Cao et al. [17] found
that baseline as well as changes in rCBV were predictive of
survival in 23 patients with high-grade gliomas. Thus, a
number of studies have shown that high rCBVor increasing
rCBV portends a poorer prognosis across multiple tumor
grades. How much value this adds to standard MRI remains
to be definitively determined.
The use of perfusion imaging to differentiate true
progression from pseudoprogression has also been an area
of interest. Barajas et al. [18￿￿] investigated DSC parame-
ters as a means of differentiating recurrent GBM from
radiation necrosis (verified by histopathology) in 57
patients. They found that mean, maximum, and minimum
relative peak height and rCBV were significantly greater in
patients with recurrent tumor than in patients with radiation
necrosis. In addition, mean, maximum, and minimum PSR
values were significantly lower in patients with recurrent
tumor than in those with radiation necrosis. However, there
was substantial overlap in rCBV values, which presents
challenges when applying a threshold to an individual
patient. Hu et al. [19] examined the use of rCBV in
differentiating high-grade glioma recurrence from post-
treatment radiation effect in 13 patients. From these
patients, they obtained 40 tissue specimens. Based on
histopathology, 16 were identified as post-treatment radia-
tion effect, and 24 were identified as recurrent glioma. In
the post-treatment radiation effect group, rCBV values
ranged from 0.21 to 0.71. In the glioma recurrence group,
rCBV values ranged from 0.55 to 4.64. Hu et al. [19] found
that an rCBV threshold value of 0.71 optimized the
differentiation of the two groups. This threshold had a
sensitivity of 91.7% and a specificity of 100%. Sugahara et
al. [20] also examined the ability of rCBV measurements to
discriminate tumor recurrence from radiation treatment
effect in mostly low- and high-grade gliomas, examining
new enhancing lesions that developed within irradiated
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recurrent tumor and less than 0.6 in cases of post-treatment
radiation effect. Thus, differentiating tumors from radiation
necrosis likely is dependent on typical rCBV values of
various tumor types. Tumors with higher rCBV (eg, grade
IV tumors and oligodendrogliomas [21]) may be more
easily distinguishable from radiation necrosis than tumors
with lower rCBV.
Although the reports from Barajas et al. [18￿￿] and Hu et
al. [19] both used DSC perfusion protocols, the ranges are
lower for both tumor and radiation necrosis in the Hu et al.
paper. Part of this difference may be due to the inclusion of
both grade III and IV tumors in the report by Hu et al. [19],
but it also is possible that differences in acquisition,
processing, and MRI platforms may result in different
thresholds across different sites even when using similar
protocols. Variability in postprocessing methods can make
comparisons across sites difficult [22]. Therefore, it will be
important to establish standardized protocols to allow for
more meaningful comparisons, particularly for the use in
multicenter trials.
Most MR perfusion protocols use gadolinium-based
contrast agents. However, Gahramanov et al. [23] argue that
due to its tendency to extravasate into the extracellular space,
gadolinium is a suboptimal contrast agent and may actually
underestimate rCBV in some patients with progressive
disease. They support the use of an iron oxide nanoparticle
called ferumoxytol, which has chemical characteristics that
are much different than gadolinium-based agents. It is
thought that ferumoxytol, due to its larger molecular size,
will exhibit significantly less extravasation from leaky
vessels into the interstitium and thus allow for a more
accurate measurement of rCBV. In their study, 14 GBM
patients with new enhancing lesions after radiation therapy
underwent DSC imaging with both gadoteridol and feru-
moxytol. In all seven cases of clinically presumptive tumor
recurrence, ferumoxytol-DSC revealed high rCBV values. In
contrast, gadoteridol-DSC (a gadolinium-based agent)
showed high rCBV values for only 4 of the 7 cases. Based
upon these results, it appears that ferumoxytol-DSC is more
sensitive in detecting true progression than gadoteridol-DSC.
However, this small study relied upon clinical status and
MRI changes to identify the enhancing lesion, and thus
histopathologic confirmation of these findings would be
desirable.
MR diffusion: functional diffusion maps and apparent
diffusion coefficient histogram analysis
Diffusion-weightingimaging(DWI)isanotherMRIsequence
under investigation in the assessment of gliomas. DWI is
based on the movement of water molecules, and the values
from these sequences are reported as the apparent diffusion
coefficient (ADC). Lower ADC values reflect lower
(more restricted) diffusion. Several physiologic properties
of tumors may influence ADC values. Water molecules
are generally more restricted in their movement within
cells and less restricted in the extracellular space.
Because necrosis involves degradation of cellular integ-
rity, it is thought that necrosis increases ADC. In a
similar way, edema increases interstitial fluid, thereby
increasing ADC. Conversely, increased cellular density
lowers ADC by restricting diffusion. Because of these
relationships, DWI has been studied as a means of
evaluating the effects of therapy on malignant gliomas.
The functional diffusion map (fDM) was developed to
take advantage of the relationship between ADC and cell
density by examining voxel-wise changes in ADC mea-
sured in the same patient over time [24–27]. By examining
voxel-wise change in ADC, the sensitivity of detecting
subtle changes in tumor cell density is dramatically
increased. This technique has primarily been applied as a
tool to predict response to cytotoxic chemotherapy and
radiotherapy within the contrast-enhancing tumor bed [24–
26]; however, recent studies have demonstrated its utility
outside regions of contrast enhancement [27–29] and as a
tool for studying the effects of anti-VEGF therapy [30, 31].
Specifically, Ellingson et al. [31] found a significant
decrease in ADC immediately following treatment with
bevacizumab; however, the rate of change of tissue
showing abnormally low ADC (fDM-classified “hyper-
cellular” tissue) within regions of T2 signal abnormality
was shown to be an early predictor of tumor progression,
time to progression, and overall survival. In other words, if
the fDM-classified hypercellular regions (low ADC) are
expanding rapidly there is a higher likelihood of tumor
recurrence and death, regardless of the specific treatment
paradigm. Figure 1 demonstrates a patient with a recurrent
GBM treated with bevacizumab and temozolomide illus-
trating substantial growth of hypercellular tumor regions
prior to standard radiographic tumor progression.
Bevacizumab treatment has been noted to produce
persistent diffusion restriction. Rieger et al. [32, 33] found
that 13 out of 18 patients with recurrent malignant gliomas
who received bevacizumab therapy exhibited diffusion-
restricted areas, along with decreased ADC values. Areas of
diffusion restriction had decreased rCBV. A biopsy of one
of the diffusion-restricted areas revealed atypical necrosis
with an upregulation of nuclear hypoxia-inducible factor-1α.
These findings suggest that prolonged antiangiogenic therapy
can result in chronic hypoxia, which, in turn, can lead to
diffusion restriction. Gerstner et al. [34]p r e s e n t e dac a s e
report in which a patient with GBM experienced persistent
diffusion restriction after bevacizumab treatment, and a
biopsy revealed infiltrative tumor. Gerstner et al. [35]a l s o
observed areas of persistent diffusion restriction after the
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with recurrent GBM treated with cediranib and found that
this treatment resulted in lower ADC values. The percent
volume of FLAIR hyperintensity comprised by low ADC
increased significantly from baseline (2.3%) to day 28
(2.9%), day 56 (5.0%), and day 112 (6.3%) of cediranib
therapy. They suggest that these findings are indicative of
increasing infiltrative tumor. However, histopathologic
correlation was not available. Because the studies by
Gerstner et al. [34, 35] and Rieger et al. [32, 33]p o i n tt o
two different pathophysiologic processes that may explain
persistent diffusion restriction, further investigation is
needed to determine whether diffusion restriction is due
to antiangiogenic effects of bevacizumab or whether it is
due to tumor recurrence. Potentially, the degree of
diffusion restriction could differentiate infiltrative tumor
from hypoxic change.
Because ADC is influenced by cellular density, necrosis,
and edema, ADC values can potentially be used as a
noninvasive surrogate for VEGF expression and thus
susceptibility to bevacizumab. We evaluated ADC histo-
gram analysis as a predictive biomarker of response to
bevacizumab in patients with recurrent GBM [36￿￿].
Regions of enhancing tumor were segmented and mapped
onto ADC images for ADC histogram generation. Tumors
with low ADC values prior to initiation of bevacizumab
were more likely to progress by 6 months compared to
those with high ADC values. This histogram analysis was
72.5% accurate in predicting 6-month progression-free
survival, and it was more accurate than the Macdonald
criteria at first follow-up. In the non–bevacizumab-treated
cohort, ADC values were not predictive of median
survival. If these findings are confirmed in a larger
study, this would be the first validated MRI-based
predictive biomarker for response to bevacizumab in
patients with GBM.
MR spectroscopy
MR spectroscopy is a technique that allows for the
characterization of the chemical makeup of a particular
region of interest. Much of the research surrounding MR
spectroscopy has focused on its potential ability to
differentiate true progression from pseudoprogression.
Smith et al. [37] studied 33 patients with primary
intracranial neoplasms and found that ratios of brain
metabolites can assist in differentiating recurrent tumor
from post-treatment radiation effect. They found that
patients with recurrent tumor had elevations in the choline
(Cho)/creatine (Cr) and Cho/N-acetylaspartate (NAA) ratios
Fig. 1 Fluid-attenuated inversion recovery (FLAIR) images and
functional diffusion maps (fDM s )i nap a t i e n tw i t hr e c u r r e n t
glioblastoma treated with bevacizumab and temozolomide. FLAIR
images showing gradual spread of nonenhancing tumor (top row).
fDMs showing increasing volume of low apparent diffusion coeffi-
cient (ADC) (“hypercellular”) regions prior to radiographic failure
(bottom row). Image days are with respect to pretreatment baseline
(day 0)
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Patients with recurrent tumor also experienced a decrease
in the NAA/Cr ratio compared to those with post-
treatment radiation effect. The Cho/NAA ratio had a
sensitivity of 85% and a specificity of 69% in detecting
true progression. In another study, Weybright et al. [38]
examined 29 patients with new contrast-enhancing brain
lesions in the vicinity of a previously treated brain
neoplasm. Histopathology was used to confirm the
identity of the lesion in 16 patients, and imaging and
clinical follow-up were used to determine the identity of
the lesion in the remaining 13 patients. Consistent with
the study conducted by Smith et al. [37], Weybright et al.
[38] found that the Cho/Cr and Cho/NAA ratios were
significantly greater in tumor recurrence compared with
post-treatment radiation effect. The NAA/Cr ratio was
significantly lower in recurrent tumor compared with
post-treatment radiation effect. Some have suggested
that creatine should not be used as a denominator in
metabolite ratios because creatine may be anticorrelated
with progression-free survival [39, 40]. Although these
studies were small, they suggest that MR spectroscopy
may be helpful in differentiating true progression from
pseudoprogression.
In addition to differentiating true progression from
pseudoprogression, the Cho/NAA ratio may also be
helpful as a biomarker for response to radiation therapy.
Oh et al. [41] studied the predictive value of the Cho/
NAA ratio in 28 patients diagnosed with GBM after
surgical resection but prior to radiation therapy. They found
that patients with a large volume of metabolic abnormality
(defined as a Cho/NAA ratio>2) had a significantly shorter
survival time than those with a small volume of metabolic
abnormality (12.0 and 17.1 months, respectively). Thus, the
Cho/NAA ratio may have predictive value in assessing
response to radiation.
Radiotracers
Radiotracers used in conjunction with positron emission
tomography (PET) scans represent another group of
potential biomarkers in assessing gliomas. By coupling
radioactive tracers to molecules that are taken up by
metabolically active cells, PETscans can detect and localize
the presence of tumors and other cells with increased
metabolism. A newer radiotracer is the nucleic acid
analogue 18 F-fluorothymidine (
18F-FLT), which is used
as an indicator of cellular proliferation. Chen et al. [42]
studied 25 patients with gliomas and found that
18F-FLT
visualized all high-grade gliomas. In contrast, 18 F-
fluorodeoxyglucose (
18F-FDG) did not detect tumor in five
patients with recurrent glioma, demonstrating that
18F-FLT
had greater sensitivity than
18F-FDG. The lower sensitivity
of
18F-FDG-PET in this study may be due to the high
background uptake of FDG in the cortex and other
metabolically active regions, whereas many other available
tracers, including FLT, have little or no uptake in normal
brain. In this study,
18F-FLT-PET was not only predictive of
time to progression and survival, but it was also more
strongly correlated with the Ki-67 staining (a histopatho-
logic marker of proliferation that has been correlated with
clinical outcomes) than
18F-FDG. In another study, Chen et
al. [43] prospectively examined 19 patients with recurrent
malignant gliomas treated with bevacizumab and irinote-
can.
18F-FLT scans were performed before the initiation of
treatment, after 1 to 2 weeks, and after 6 weeks; response
was defined as a reduction in
18F-FLT uptake by more than
25% after 6 weeks. Those who responded based on
18F-
FLT uptake survived three times as long as those who did
not respond (10.8 vs 3.4 months). Both early and late
18F-
FLT responses were significant predictors of overall
survival. These studies suggest that
18F-FLT has significant
promise as a biomarker of outcome in patients with GBM,
which can be acquired relatively early in the treatment
cycle.
Amino acid tracers have also been studied. Potzi et al.
[44] studied methyl-
11C-l-methionine (
11C-methionine) as a
means of assessing GBM in 28 patients. Although
11C-
methionine uptake detected tumor in 24 out of 28 patients,
there was no correlation between uptake and survival
outcomes. Because it does not correlate with clinical
outcomes,
11C-methionine may not be suitable as a
response marker like
18F-FLT, but may be more suitable
for detecting disease recurrence, including nonenhancing
tumor. For instance, Galldiks et al. [45] studied 12 patients
with recurrent GBM and found that metabolically active
tumor volume (defined as
11C-methionine uptake≥1.3) was
significantly larger than the volume of gadolinium-enhanced
tumor (30.17 vs 13.7 cm
3). One drawback of
11C-methionine
is its half-life of 20 min. Due to its short half-life,
11C-
methionine cannot be used in PETcenters without a cyclotron,
limiting its clinical utility.
18F-labeled amino acid analogues
with longer half-lives (eg, 3,4-dihydroxy-6-[18]F-fluoro-l-
phenylalanine [
18F-FDOPA]) have also been used to assess
gliomas. Becherer et al. [46] studied 20 patients with
supratentorial brain lesions (18 of which were primary
brain tumors) and found that mean standardized uptake ratios
were similar for
18F-FDOPA and
11C-methionine (2.05 and
2.04, respectively). Chen et al. [47] examined the diagnostic
accuracy of
18F-FDOPA in assessing gliomas. They studied
81 patients with brain tumors and found that
18F-FDOPA had
a sensitivity of 98%, a specificity of 86%, a positive predictive
value of 95%, and a negative predictive value of 95%. These
studies indicate that amino acid tracers can reliably detect
gliomas, and their ability to discriminate gliosis from
nonenhancing tumor merits additional investigation.
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The search for clinically useful biomarkers for treatment
response in malignant gliomas has been challenging.
Recently, attempts to assess gliomas using imaging have
broadened in focus from strictly anatomic measurements to
evaluating the utility of MRI techniques that quantify
changes in tumor physiology. Based on preliminary
studies, new physiologic imaging techniques may have
the ability to detect drug susceptibility or resistance prior
to changes in tumor size. If these efforts are successful,
this could allow for earlier treatment decisions and more
individually tailored medicine. Unfortunately, the clini-
cal utility of these physiologic imaging techniques
remains unproven and the methods unstandardized. To
date, no perfusion-based imaging biomarkers have been
validated in large trials. ADC histogram analysis has
been preliminarily shown to have predictive value in
predicting response to bevacizumab. Confirmation in a
larger study is ongoing. As advances occur in the
development of therapies that target specific biochem-
ical pathways and alter tumor physiology in potentially
predictable ways, the validation of physiologic biomarkers
will become increasingly important.
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